Safety, Growth and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up).

Context: The T2NOW trial of dapagliflozin or saxagliptin versus placebo in pediatric patients with type 2 diabetes (T2D) demonstrated promising efficacy data for dapagliflozin and did not raise any safety concerns over 52 weeks.

Objective: Assess long-term effects of prior dapagliflozin/saxagliptin administration on safety, growth and development.

Design: Multicenter, randomized, double-blind phase 3 trial (T2NOW).

Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes.

BACKGROUND: Incidence of type 2 diabetes (T2D) in children and adolescents is increasing, but treatment options are limited. METHODS: This was a 26-week, phase 3 trial with a 26-week extension among patients (10 to 17 years of age) with uncontrolled T2D (A1C 6.5 to 10.

Obesity Affects Submaximal Oxygen Uptake-Heart Rate Relationship and Exercise Economy Differently in Pre- and Post-pubescent Boys and Girls.

The purpose of this study was to develop regression equations for estimating the intensity of the exercise work rate (relative peak oxygen uptake-heart rate [%VO-HR]) and the metabolic energy expenditure (MEE) for exercise prescription and rehabilitation medicine that are specific to children. This study took into account that the specific data in terms of obesity, sex, and pubertal status are currently unavailable. Our hypothesis was that obesity would affect the submaximal exercise the oxygen uptake (VO), heart rate (HR), and metabolic energy expenditure (MEE), and exercise economy (ExEco).

Exercise management in type 1 diabetes: a consensus statement.

Type 1 diabetes is a challenging condition to manage for various physiological and behavioural reasons. Regular exercise is important, but management of different forms of physical activity is particularly difficult for both the individual with type 1 diabetes and the health-care provider. People with type 1 diabetes tend to be at least as inactive as the general population, with a large percentage of individuals not maintaining a healthy body mass nor achieving the minimum amount of moderate to vigorous aerobic activity per week.

Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome.

Prader-Willi syndrome (PWS), the leading genetic cause of obesity, is characterized by a striking hyperphagic behavior that can lead to obesity, type-2 diabetes, cardiovascular disease and death. The molecular mechanism underlying impaired satiety in PWS is unknown. Oleoylethanolamide (OEA) is a lipid mediator involved in the control of feeding, body weight and energy metabolism.